School of Nursing and Midwifery, Griffith University, Nathan, Queensland, Australia.
Alliance for Vascular Access Teaching and Research Group, Menzies Health Institute Queensland, Nathan, Queensland, Australia.
BMC Cancer. 2017 Aug 30;17(1):595. doi: 10.1186/s12885-017-3606-9.
Central venous access device (CVAD) associated complications are a preventable source of patient harm, frequently resulting in morbidity and delays to vital treatment. Dressing and securement products are used to prevent infectious and mechanical complications, however current complication rates suggest customary practices are inadequate. The aim of this study was to evaluate the feasibility of launching a full-scale randomized controlled efficacy trial of innovative dressing and securement products for pediatric tunneled CVAD to prevent complication and failure.
An external, pilot, four-group randomized controlled trial of standard care (bordered polyurethane dressing and suture), in comparison to integrated securement-dressing, suture-less securement device, and tissue adhesive was undertaken across two large, tertiary referral pediatric hospitals in Australia. Forty-eight pediatric participants with newly inserted tunneled CVADs were consecutively recruited. The primary outcome of study feasibility was established by elements of eligibility, recruitment, attrition, protocol adherence, missing data, parent and healthcare staff satisfaction and acceptability, and effect size estimates for CVAD failure (cessation of function prior to completion of treatment) and complication (associated bloodstream infection, thrombosis, breakage, dislodgement or occlusion). Dressing integrity, product costs and site complications were also examined.
Protocol feasibility was established. CVAD failure was: 17% (2/12) integrated securement-dressing; 8% (1/13) suture-less securement device; 0% tissue adhesive (0/12); and, 0% standard care (0/11). CVAD complications were: 15% (2/13) suture-less securement device (CVAD associated bloodstream infection, and occlusion and partial dislodgement); 8% (1/12) integrated securement-dressing (partial dislodgement); 0% tissue adhesive (0/12); and, 0% standard care (0/11). One CVAD-associated bloodstream infection occurred, within the suture-less securement device group. Overall satisfaction was highest in the integrated securement-dressing (mean 8.5/10; standard deviation 1.2). Improved dressing integrity was evident in the intervention arms, with the integrated securement-dressing associated with prolonged time to first dressing change (mean days 3.5).
Improving the security and dressing integrity of tunneled CVADs is likely to improve outcomes for pediatric patients. Further research is necessary to identify novel, effective CVAD securement to reduce complications, and provide reliable vascular access for children.
ACTRN12614000280606 ; prospectively registered on 17/03/2014.
中心静脉置管(CVAD)相关并发症是可预防的患者伤害源,经常导致发病率和关键治疗的延迟。敷料和固定产品用于预防感染和机械并发症,但是目前的并发症发生率表明常规做法不足。本研究的目的是评估为预防儿科隧道式 CVAD 并发症和失效而推出创新的敷料和固定产品的全面随机对照疗效试验的可行性。
在澳大利亚的两家大型三级转诊儿科医院中,对标准护理(带边框的聚氨酯敷料和缝线)进行了外部、初步、四组随机对照试验,与集成固定敷料、无缝线固定装置和组织胶进行了比较。连续招募了 48 名新插入隧道式 CVAD 的儿科参与者。研究可行性的主要结果是通过符合条件、招募、流失、遵守方案、数据缺失、父母和医护人员满意度和可接受性以及 CVAD 失效(在完成治疗之前停止功能)和并发症(相关血流感染、血栓形成、断裂、脱位或阻塞)的效果大小估计来确定的。还检查了敷料完整性、产品成本和部位并发症。
建立了方案可行性。CVAD 失效的比例分别为:17%(2/12)集成固定敷料;8%(1/13)无缝线固定装置;0%组织胶(0/12);0%标准护理(0/11)。CVAD 并发症的比例分别为:15%(1/13)无缝线固定装置(CVAD 相关血流感染、闭塞和部分脱位);8%(1/12)集成固定敷料(部分脱位);0%组织胶(0/12);0%标准护理(0/11)。在无缝线固定装置组中发生了一例与 CVAD 相关的血流感染。在集成固定敷料中总体满意度最高(平均 8.5/10;标准差 1.2)。干预组中明显改善了敷料的完整性,集成固定敷料与首次更换敷料的时间延长有关(平均 3.5 天)。
提高隧道式 CVAD 的安全性和敷料完整性可能会改善儿科患者的结局。需要进一步研究以确定新的、有效的 CVAD 固定装置,以减少并发症,并为儿童提供可靠的血管通路。
ACTRN12614000280606;2014 年 3 月 17 日前瞻性注册。